References

  1. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2015-2016 influenza season. Morbidity and Mortality Weekly Report (MMWR). 2015;64(30):818-828.
  2. DiazGranados CA, Dunning AJ, Robertson CA, et al. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty. Vaccine. 2015;33(36):4565-4571.
  3. Sheridan PA, Paich HA, Handy J, et al. The antibody response to influenza vaccination is not impaired in type 2 diabetics. Vaccine. 2015;33(29):3306-3313.
  4. Principi N, Esposito S; ESCMID Vaccine Study Group (EVASG). Influenza vaccination in patients with end-stage renal disease. Expert Opin Drug Saf. 2015;14(8):1249-1258.
  5. Prevato M, Ferlenghi I, Bonci A, et al. Expression and characterization of recombinant, tetrameric and enzymatically active influenza neuraminidase for the setup of an enzyme-linked lectin-based assay. PLoS One. 2015;10(8):e0135474.
  6. Tan Y, He F, Kwang J. How can we develop universal H5N1 vaccines. Immunotherapy. 2015 Aug 7:1-4. [Epub ahead of print]
  7. Chesarino NM, McMichael TM, Yount JS. E3 ubiquitin ligase NEDD4 promotes influenza virus infection by decreasing levels of the antiviral protein IFITM3. Ashour J, ed. PLoS Pathogens. 2015;11(8):e1005095.